Search research articles
Contact Us
Filters
Showing results (181-190 of 198) with videos related to
Page
of 20
Sort By:
Cell
|
March 17, 2023
Dynamic CD8<sup>+</sup> T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes
Maha K Rahim, Trine Line H Okholm, Kyle B Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Toni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.
Immunity
|
February 10, 2019
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
Chien-Chun Steven Pai, John T Huang, Xiaoqing Lu, et al.
Science (New York, N.Y.)
|
April 7, 2022
Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus
Richard K Perez, M Grace Gordon, Meena Subramaniam, et al.
Cancer Immunology Research
|
March 29, 2024
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Atish D Choudhury, Lucia Kwak, Alexander Cheung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Joaquim Bellmunt, Ronald de Wit, Yves Fradet, et al.
Nature Medicine
|
October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature Medicine
|
June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Cancer Discovery
|
November 17, 2019
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Lawrence Fong, Andrew Hotson, John D Powderly, et al.
Nature Medicine
|
March 5, 2021
Transcriptional mediators of treatment resistance in lethal prostate cancer
Meng Xiao He, Michael S Cuoco, Jett Crowdis, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 198) with videos related to
Sort By:
Page
of 20
Cell
|
March 17, 2023
Dynamic CD8<sup>+</sup> T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes
Maha K Rahim, Trine Line H Okholm, Kyle B Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Toni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.
Immunity
|
February 10, 2019
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
Chien-Chun Steven Pai, John T Huang, Xiaoqing Lu, et al.
Science (New York, N.Y.)
|
April 7, 2022
Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus
Richard K Perez, M Grace Gordon, Meena Subramaniam, et al.
Cancer Immunology Research
|
March 29, 2024
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Atish D Choudhury, Lucia Kwak, Alexander Cheung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Joaquim Bellmunt, Ronald de Wit, Yves Fradet, et al.
Nature Medicine
|
October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Nature Medicine
|
June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Cancer Discovery
|
November 17, 2019
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Lawrence Fong, Andrew Hotson, John D Powderly, et al.
Nature Medicine
|
March 5, 2021
Transcriptional mediators of treatment resistance in lethal prostate cancer
Meng Xiao He, Michael S Cuoco, Jett Crowdis, et al.
Page
of 20